Acid-NSAID/aspirin interaction in peptic ulcer disease

Digestive Diseases

Volumn 29, Issue 5, 2011, Pages 465-468

  Hunt, Richard H ^a   Yuan, Yuhong ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Acid suppression; Aspirin damage; Clopidogrel; COX 2 selective inhibitors; PPI co therapy

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ACID; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; GASTRIC ACID; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS;

EID: 81755171146     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000332211     Document Type: Article

References (23)

1. Gustafson J, Welling D: 'No acid, no ulcer'-100 years later: a review of the history of peptic ulcer disease. J Am Coll Surg 2010; 210:110-116.
2. Chan FK, Sung JJ: Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001; 15:433-445. (Pubitemid 32590877)
3. Scarpignato C, Hunt RH: Non-steroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39:433-464.
4. Huang JQ, Sridhar S, Hunt RH: Role of Heli-cobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22. (Pubitemid 34119190)
5. Venerito M, Malfertheiner P: Interaction of Helicobacter pylori infection and non-steroi-dal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010; 15: 239-250.
6. Lanas A, Hunt R: Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38:415-428. (Pubitemid 44484879)
7. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 18 4 9-18 6 0.
8. Nishino M, Sugimoto M, Kodaira C, et al: Relationship between low-dose aspirin-induced gastric mucosal injury and intragas-tric pH in healthy volunteers. Dig Dis Sci 2010; 55:1627-1636.
9. Rostom A, Dube C, Wells G, et al: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Library, 2007, issue 2.
10. Nishino M, Sugimoto M, Kodaira C, et al: Preventive effects of lansoprazole and fa-motidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011; 51: 10 79-10 86.
11. Padol IT, Hunt RH: Association of myocar-dial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology (Oxford) 2010; 49: 837-843.
12. Chan FK, Lanas A, Scheiman J, et al: Cele-coxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 17 3-17 9.
13. Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group: Canadian consensus guidelines on long-term non-steroidal anti-inflammatory drug therapy and the need for gastroprotec-tion: benefits versus risks. Aliment Pharmacol Ther 2009; 29:481-496.
14. Wang CC, Yuan Y, Chen Y, Hunt RH: Nighttime pH holding time: what is hidden by the % of time pH ^ 4? Am J Gastroenterol 2008; 103(suppl 1):S51.
15. Goldstein JL, Hochberg MC, Fort JG, et al: Clinical trial: the incidence of NSAID-asso-ciated endoscopic gastric ulcers in patients treated with PN-400 (naproxen + esomepra-zole magnesium) vs. enteric-coated naprox-en alone. Aliment Pharmacol Ther 2010; 32: 401-413.
16. Lanas A: Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011; 10:45-54.
17. Ng FH, Wong SY, Lam KF, et al: Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterolog y 2010; 138: 82-88.
18. Earnshaw SR, Scheiman J, Fendrick AM, et al: Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171:218-225.
19. Bhatt DL, Scheiman J, Abraham NS, et al: AC CF/ACG/A H A 2 0 0 8 ex per t c ons en s u s document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103:2890-2907.
20. Gilard M, Arnaud B, Cornily JC, et al: Influence of omepra zole on t he antiplatelet act ion of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omepra-zole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
21. L e ont iad is GI, Yu a n Y, Howd e n C: T he i nt e r-action between PPIs and clopidogrel and upper gastrointestinal bleeding. Gastrointest Endosc Clin North Am 2011;21:637-656.
22. Bhatt DL, Cryer BL, Contant CF, et al for the COGENT Investigators: Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 190 9-1917.
23. Bardou M, Barkun AN: Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010; 77: 6-12.